Hepatocellular Carcinoma - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 939
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDDA6A0D3B4EN
Leaflet:

Download PDF Leaflet

Hepatocellular Carcinoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Hepatocellular Carcinoma - Pipeline Review, H2 2015’, provides an overview of the Hepatocellular Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Hepatocellular Carcinoma Overview
Therapeutics Development
Hepatocellular Carcinoma - Therapeutics under Development by Companies
Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Pipeline Products Glance
Hepatocellular Carcinoma - Products under Development by Companies
Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
Hepatocellular Carcinoma - Therapeutics Assessment
Drug Profiles
Hepatocellular Carcinoma - Recent Pipeline Updates
Hepatocellular Carcinoma - Dormant Projects
Hepatocellular Carcinoma - Discontinued Products
Hepatocellular Carcinoma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Hepatocellular Carcinoma, H2 2015
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2015
Hepatocellular Carcinoma - Pipeline by AB Science SA, H2 2015
Hepatocellular Carcinoma - Pipeline by AbbVie Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H2 2015
Hepatocellular Carcinoma - Pipeline by Adaptimmune Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2015
Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Amgen Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by AndroScience Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Arbutus Biopharma Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by ArQule, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2015
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2015
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by Bioneer Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines, H2 2015
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Hepatocellular Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Hepatocellular Carcinoma - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2015
Hepatocellular Carcinoma - Pipeline by Celgene Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Celsion Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by CrystalGenomics, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by CytRx Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Delcath Systems, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Digna Biotech, S.L., H2 2015
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2015
Hepatocellular Carcinoma - Pipeline by e-Therapeutics Plc, H2 2015
Hepatocellular Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2015
Hepatocellular Carcinoma - Pipeline by Endocyte, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Exelixis, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Genelux Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2015
Hepatocellular Carcinoma - Pipeline by GenSpera, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp., H2 2015
Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2015
Hepatocellular Carcinoma - Pipeline by Huperion Sarl, H2 2015
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2015
Hepatocellular Carcinoma - Pipeline by Immunitor, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Immunomedics, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Immuron Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by In-Cell-Art S.A.S., H2 2015
Hepatocellular Carcinoma - Pipeline by Incuron, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies B.V., H2 2015
Hepatocellular Carcinoma - Pipeline by Jenrin Discovery, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2015
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Kite Pharma, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Komipharm International Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Kowa Company, Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H2 2015
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by MaxCyte, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by MedImmune, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by Medivation, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2015
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2015
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Mirna Therapeutics, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by MolMed S.p.A., H2 2015
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by NormOxys, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2015
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Omeros Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by OncoTherapy Science, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2015
Hepatocellular Carcinoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Orega Biotech SAS, H2 2015
Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Pfizer Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Pharma Mar, S.A., H2 2015
Hepatocellular Carcinoma - Pipeline by PharmAbcine, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corporation, H2 2015
Hepatocellular Carcinoma - Pipeline by PhaseRx, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Progen Pharmaceuticals Limited, H2 2015
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2015
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Raptor Pharmaceutical Corp., H2 2015
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2015
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2015
Hepatocellular Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Theravectys SA, H2 2015
Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Tumorend, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2015
Hepatocellular Carcinoma - Pipeline by Vect-Horus S.A.S., H2 2015
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc., H2 2015
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics, LLC, H2 2015
Hepatocellular Carcinoma - Pipeline by Virttu Biologics Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hepatocellular Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Hepatocellular Carcinoma - Dormant Projects, H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..6), H2 2015
Hepatocellular Carcinoma - Dormant Projects (Contd..7), H2 2015
Hepatocellular Carcinoma - Discontinued Products, H2 2015
Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2015
Hepatocellular Carcinoma - Discontinued Products (Contd..2), H2 2015

LIST OF FIGURES

Number of Products under Development for Hepatocellular Carcinoma, H2 2015
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
ACROVIS Pharma AG
Adaptimmune Limited
Advenchen Laboratories, LLC
Alfact Innovation
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
AndroScience Corporation
Arbutus Biopharma Corporation
ArQule, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Bio-Cancer Treatment International Limited
Bioneer Corporation
Blueprint Medicines
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Can-Fite BioPharma Ltd.
CASI Pharmaceuticals Inc.
CCRP Therapeutics GmbH
Celgene Corporation
Celldex Therapeutics, Inc.
Celsion Corporation
China Medical System Holdings Limited
Chroma Therapeutics Limited
CrystalGenomics, Inc.
CytRx Corporation
Delcath Systems, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Double Bond Pharmaceutical International AB
e-Therapeutics Plc
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genelux Corporation
Genoscience Pharma
GenSpera, Inc.
GlaxoSmithKline Plc
Golden Biotechnology Corp.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Horizon Pharma Plc
Huperion Sarl
Immunicum AB
Immunitor, Inc.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Immuron Limited
In-Cell-Art S.A.S.
Incuron, LLC
InteRNA Technologies B.V.
Jenrin Discovery, Inc.
Johnson & Johnson
KAHR medical Ltd.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Kowa Company, Ltd.
Les Laboratoires Servier SAS
Ligand Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
MaxCyte, Inc.
MedImmune, LLC
Medivation, Inc.
Medivir AB
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
MolMed S.p.A.
MultiCell Technologies, Inc.
Nimbus Therapeutics, LLC
NormOxys, Inc.
Novartis AG
Nymox Pharmaceutical Corporation
Omeros Corporation
Oncolys BioPharma Inc.
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Onyx Pharmaceuticals, Inc.
Orega Biotech SAS
Otsuka Holdings Co., Ltd.
Panacea Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
PharmAbcine, Inc.
PharmaEssentia Corporation
PhaseRx, Inc.
Polaris Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Raptor Pharmaceutical Corp.
RedHill Biopharma Ltd.
Regulus Therapeutics Inc.
Rigontec GmbH
Saronic Biotechnology, Inc.
Shenogen Pharma Group Ltd.
Shenzen SiBiono GeneTech Co., Ltd
Sillajen Biotherapeutics
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Therapure Biopharma Inc.
Theravectys SA
Threshold Pharmaceuticals, Inc.
Toko Pharmaceutical Industries Co., Ltd.
TRACON Pharmaceuticals, Inc.
Tumorend, LLC
VasGene Therapeutics, Inc.
Vaxon Biotech
Vect-Horus S.A.S.
Verlyx Pharma Inc.
Vicus Therapeutics, LLC
Virttu Biologics Limited
Skip to top


Renal Cell Carcinoma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 793 pages

Ask Your Question

Hepatocellular Carcinoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: